methamphetamine (desoxyn) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Methamphetamine is a potent central nervous system (CNS) stimulant that is mainly used as a recreational drug and less commonly as a second-line treatment for attention deficit hyperactivity disorder and obesity. Methamphetamine was discovered in 1893 and exists as two enantiomers: levo-methamphetamine and dextro-methamphetamine. Methamphetamine properly refers to a specific chemical substance, the racemic free base, which is an equal mixture of levomethamphetamine and dextromethamphetamine in their pure amine forms, but the hydrochloride salt, commonly called crystal meth, is widely used. Methamphetamine is rarely prescribed over concerns involving human neurotoxicity and potential for recreational use as an aphrodisiac and euphoriant, among other concerns, as well as the availability of safer substitute drugs with comparable treatment efficacy such as Adderall and Vyvanse. Dextromethamphetamine is a stronger CNS stimulant than levomethamphetamine.   Wikipedia

Chemistry

More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$4.5226 - $6.8607
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(alphas)-n,alpha-dimethylbenzeneethanamine | d-amphetamine | desoxyephedrine hcl | desoxyn | d-methamphetamine | d-methylamphetamine | d-n-methylamphetamine | d-phenylisopropylmethylamine | l-desoxyephedrine | levmetamfetamine | levomethamphetamine | l-methamphetamine | l-methylamphetamine | metamfetamine | métamfétamine | metamfetaminum | metanfetamina | methampex | methamphetamine | methamphetamine hcl | methamphetamine hydrochloride | methamphetaminum | methylamfetamine hydrochloride | methylamphetamine | methyl-beta-phenylisopropylamine | methyl-β-phenylisopropylamine | (r)-deoxyephedrine | (r)-methamphetamine | (r)-methylamphetamine | (s)-methamphetamine | (s)-n,alpha-dimethylbenzeneethanamine | (+)-(s)-n-alpha-dimethylphenethylamine | (s)-n,α-dimethylbenzeneethanamine | (+)-(s)-n-α-dimethylphenethylamine | (αs)-n,α-dimethylbenzeneethanamine

Organizations (21)

Research & Development (11)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (19)

Approved Indications (6)


 

Attention Deficit Disorder with Hyperactivity (approved 1943)

Common Cold

Hypersensitivity

Narcolepsy

Obesity (approved 1943)

Rhinitis, Allergic, Seasonal

Experimental Indications - Clinical Trial Phases 1-4 (13)


 

Affect (Early Phase 1)

Cardiovascular Abnormalities (Phase 1)

Central Nervous System Stimulants (Early Phase 1)

Cocaine-Related Disorders (Early Phase 1)

Drug Interactions (Phase 1)

Healthy Volunteers (Phase 1)

HIV Infections (Phase 4)

Methamphetamine (Phase 4)

Motivation (Early Phase 1)

N-Methyl-3,4-methylenedioxyamphetamine (Early Phase 1)

Obsessive-Compulsive Disorder (Phase 2)

Social Behavior (Early Phase 1)

Substance-Related Disorders (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 18
  • # of Trial Organizations: 11

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue